Multi-Component Nutraceuticals Stabilize Extracellular Matrix

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current medical approaches to breast cancer prevention and treatment are inadequate, with chemotherapy showing limited success in improving long-term survival rates, and the prevailing paradigm focusing on cellular-level intervention has been criticized for its inefficacy in addressing the underlying causes of cancer.

Innovation Solution

Development of multi-component nutraceutical compositions comprising catechins, curcuminoids, isothiocyanates, stilbenoids, and therapeutic essential oils that stabilize the extracellular matrix (ECM), inhibit aberrant biological pathways, and modulate inflammatory responses, thereby preventing or treating chronic diseases, including breast cancer.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chemotherapy is used to treat breast cancer, then tumor cells are killed, but long-term survival rates show minimal improvement and severe side effects occur

Engineering Contradiction:

Improvecancer treatment effectivenessVSAvoidside effects and mortality

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The treatment approach is segmented into multiple independent pathways: stabilizing ECM structure, inhibiting specific enzymatic activities (MMPs, LOX, COX-2), blocking inflammatory cascades, and modulating cellular signaling. Each pathway is targeted by specific phytochemical compounds working synergistically rather than relying on a single cytotoxic mechanism.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Phytochemical compounds serve as intermediaries that mediate between the extracellular matrix environment and cellular behavior. These compounds stabilize ECM proteins, inhibit proteolytic degradation, and modulate cell-matrix interactions to prevent malignant transformation and promote differentiation, avoiding direct cellular destruction.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If the prevailing cellular-level intervention paradigm is employed, then cancer cells are targeted, but the underlying causes related to ECM destabilization remain unaddressed

Engineering Contradiction:

Improvecancer treatment effectivenessVSAvoidability to address underlying causes

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

Instead of starting with cellular intervention and hoping to affect the microenvironment, this approach inverts the strategy by first stabilizing the extracellular matrix and creating a healthy tissue environment, which then exerts protective and differentiating effects on cells. The causality is reversed: ECM stability precedes and prevents cellular malignancy rather than cellular therapy attempting to restore ECM.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The treatment addresses ECM destabilization and inflammatory pathways before cancer fully develops or progresses. By stabilizing the extracellular matrix and inhibiting proteolytic and inflammatory cascades early in the disease process, the approach prevents the microenvironmental conditions that would otherwise promote malignant transformation and progression.

Inventive Principle:

Principle #10Preliminary action

3Device complexity

If single-component therapies are used, then treatment simplicity is maintained, but efficacy in stabilizing ECM and inhibiting multiple aberrant pathways is insufficient

Engineering Contradiction:

Improvetreatment composition complexityVSAvoidECM stabilization and pathway inhibition efficacy

Core Design Contradiction:

Device complexityVSReliability

Solution Approach 1:

Multiple phytochemical compounds with distinct mechanisms of action are merged into a single therapeutic formulation. These compounds collectively stabilize ECM proteins, inhibit multiple protease families (MMPs, cathepsins), block inflammatory enzymes (LOX, COX-2), and modulate cellular signaling pathways, providing comprehensive coverage of the disease process through synergistic interaction.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The treatment employs a composite formulation combining diverse phytochemical compounds that target different molecular pathways and structures. This composite approach mirrors the complexity of the disease process by simultaneously addressing ECM stability, proteolytic activity, inflammatory cascades, and cellular signaling through multiple complementary mechanisms.

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS9610258B2Methods of stabilizing the extracellular matrix and compositions therefor

Publication Date: 2017.04.04 MD MATRIX HEALTH LLC DBA MD MATRIX HEALTH

AI summary

Disclosed are prophylactic and therapeutic methods, as well as dosing regimens and medicaments for use in preventing chronic disease, for treating acute or long-term inflammatory-mediated conditions in affected or at-risk subjects, and for stabilizing one or more components of the mammalian extracellular matrix. Also disclosed are pharmaceutical compositions and topical formulations thereof that include multiple, phytochemically-active, nutraceutical compounds, and that possess potent anti-inflammatory and extracellular matrix-stabilizing properties both in vitro and in vivo.